Patient Menu At Kabul Hospitals Sparks Concerns
Relatives have expressed concerns about the provision of unsuitable food for jaundice patients at two hospitals in Kabul, but ...
The Manila Times14h
MDB Capital Holdings Provides Fourth Quarter and Full Year 2024 Update
Addison, TX, March 31, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) ("MDB”), a public venture platform ...
Special drive to detect fatty liver disease in city next month: Seth
Ranchi: Ranchi is set to become the first district in Jharkhand to implement a large-scale campaign for the screening and ...
PharmiWeb19h
IMFINZI® (durvalumab) approved in the US as first…
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Gastroenterology Advisor19h
Cholecystectomy Hx Linked to Increased Colonic Bubbles, Longer Colonoscopy Times
Patients with a history of cholecystectomy are more likely to develop colonic bubbles during colonoscopy, a retrospective cohort study found.
CURE21h
Inside the Mind of a Bile Duct Cancer Survivor
I’ve spent 14 years navigating recovery, mental health challenges and giving back to the cancer community through patient ...
Tharimmune announces FDA feedback on NDA path for TH104
Tharimmune (THAR) announced in addition to developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with ...
Tharimmune announces FDA feedback on TH104 NDA path
Tharimmune (THAR) announced in addition to developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with ...
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...